Baker Bros bags $340m from BeiGene block
Baker Bros Advisors, a shareholder in Chinese biopharmaceutical company BeiGene, has raised $340.1m from a sell-down of the firm’s American depositary shares.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: